Drugs / calcium aluminosilicate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00748215 | Feb 2009 → Aug 2014 | chemotherapy-induced toxicity, colorectal cancer, diarrheal disease | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | calcium aluminosilicate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00748215 ↗ |
| Known as | CASAD | “calcium aluminosilicate anti-diarrheal (CASAD) may help treat and prevent diarrhea caused by irinotecan.” NCT00748215 ↗ |
| Route | Oral | “Given orally” NCT00748215 ↗ |